Institutional Review Board (IRB)

Ensuring rights & welfare of human subjects in research

Research conducted by NEOMED using human participants is overseen by the Institutional Review Board (IRB). The primary purpose of the NEOMED IRB is to facilitate the review, approval, modification, and disapproval of human subject research protocols, while ensuring the rights and welfare of human subjects are protected while participating in research.  The NEOMED IRB is registered to review research governed by the Office of Human Research Protections (OHRP).  NEOMED has partnered with Advarra, a commercial outside IRB, to provide review and oversite of research governed by the Federal Drug Administration (FDA).

The IRB process at NEOMED is based on rules and regulations for federally funded research, primarily the Code of Federal Regulation (45 CFR 46) and supporting materials such as the Belmont Report.


Interim IRB Chair: Kirk Stiffler, M.D.
IRB Vice-Chair:  Natalie Bonfine, Ph.D. ext. 6182
Human Protections Administrator: Steve Schmidt, Ph.D., ext. 6290
Committee Coordinator: Trish Wilson, CRA, ext. 6364
Please submit all materials electronically for IRB review to Trish Wilson, CRA, Regulatory Affairs Coordinator,

Meeting Dates

For protocols which are above minimal risk and do not quality of exempt or expedited review:

  • January 25, 2021 at 4 p.m.
  • March 08, 2021 at 4 p.m.
  • May 17, 2021 at 4 p.m.
  • July 12, 2021 at 4 p.m.
  • September 13, 2021 at 4 p.m.
  • November 08, 2020 at 4 p.m.


All materials must be submitted two weeks prior to the full board meeting date.  Submit all materials electronically to the Regulatory Affairs Coordinator at


Trish Wilson, CRA
Regulatory Affairs Coordinator
Phone: 330.325.6364

Institutional Review Board (IRB)

Research Administration at NEOMED